Newland Pharmaceutical Co Ltd
SZSE:301277
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (30.3), the stock would be worth ¥1.21 (89% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 285.8 | ¥11.4 |
0%
|
| 3-Year Average | 30.3 | ¥1.21 |
-89%
|
| 5-Year Average | 30.8 | ¥1.23 |
-89%
|
| Industry Average | 35.7 | ¥1.42 |
-88%
|
| Country Average | 26.4 | ¥1.05 |
-91%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
N
|
Newland Pharmaceutical Co Ltd
SZSE:301277
|
4.5B CNY | 285.8 | 36.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
Newland Pharmaceutical Co Ltd
Glance View
Newland Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Xuchang, Henan and currently employs 800 full-time employees. The company went IPO on 2022-11-16. Newland Pharmaceutical Co Ltd, formerly Henan Newland Pharmaceutical Co Ltd, is a China-based company mainly engaged in pharmaceutical research and development. The firm's main business is the research and development, production and sales of pharmaceutical intermediates. The firm's main products are L-p-hydroxyphenylglycine series products and p-toluenesulfonic acid, including D-acid, methyl ester and hydroxydeng salt. The firm also produces pharmaceutical resolution agents. The firm mainly operates its businesses in the domestic and overseas markets.
